<DOC>
	<DOCNO>NCT00282555</DOCNO>
	<brief_summary>STU-Na belongs proton pump inhibitor ( PPI ) , group drug reduce gastric acidity . PPI use treat acid related disease like erosive ulcerative esophagitis . This trial aim find therapeutic dose STU-Na require heal patient erosive ulcerative esophagitis . One four dosage STU-Na ( 15 mg , 30 mg , 60 mg , 90 mg daily ) , Esomeprazole 40 mg daily , already market PPI , give patient . The attribution one 5 treatment group chance . Neither patient study physician know , treatment administer patient .</brief_summary>
	<brief_title>Efficiency Study S-Tenatoprazole-Na Treat Erosive Ulcerative Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<criteria>Male female outpatient age 18 75 year inclusive Symptomatic ulcerative erosive esophagitis Presence heartburn ( daytime and/or nighttime ) . Understanding study agree give write informed consent Able communicate well investigator ( ) self his/her representative Able agree comply study requirement gastrointestinal bleed gastric esophageal surgery ZollingerEllison syndrome primary esophageal motility disorder , esophageal stricture , inflammatory bowel disease , upper gastrointestinal malignancy , pancreatitis , malabsorption Barrett 's esophagus ( &gt; 3 cm ) Severe disease/condition malignancy Hypersensitivity PPIs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Esophagitis , Reflux</keyword>
	<keyword>S-Tenatoprazole-Na</keyword>
	<keyword>Heartburn</keyword>
	<keyword>Esophageal endoscopy</keyword>
</DOC>